SCHEMBL25922300

SCHEMBL25922300

CCCCN1C(=O)CSc2ccc(C(=O)Nc3ccc(S(=O)(=O)N4CCCCC4)cc3)cc21

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CTDSP1 Q9GZU7 1/20 0.61
▸ POLB P06746 3/20 0.57
▸ KMT2A Q03164 3/20 0.56
▸ KDM4E B2RXH2 1/20 0.56
▸ TAAR1 Q96RJ0 1/20 0.56
▸ TP53 P04637 1/20 0.55
▸ MAPT P10636 4/20 0.53
▸ MEN1 O00255 2/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ CYP3A4 P08684 1/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ USP2 O75604 2/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ GAA P10253 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ LMNA P02545 2/20 0.51
▸ TDP1 Q9NUW8 1/20 0.50
▸ RXFP1 Q9HBX9 1/20 0.50
▸ TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25922340 0.91 CTDSP1 (0.64) CTDSP1POLBKMT2AKDM4EMAPT
SCHEMBL25927899 0.88 CTDSP1 (0.55) CTDSP1POLBKMT2AKDM4ETAAR1
SCHEMBL25921866 0.87 CYP1A2 (0.58) CTDSP1POLBKMT2AKDM4ETP53
SCHEMBL30270587 0.87 CYP1A2 (0.58) CTDSP1POLBKMT2AKDM4ETP53
SCHEMBL25922279 0.85 CTDSP1 (0.58) CTDSP1POLBKMT2AKDM4ETP53
SCHEMBL24124885 0.84 ALDH1A1 (0.52) CTDSP1POLBKMT2AKDM4ETP53
SCHEMBL25922344 0.83 CYP1A2 (0.56) CTDSP1POLBKMT2AKDM4ETP53
SCHEMBL25922275 0.80 TP53 (0.59) CTDSP1POLBKMT2AKDM4ETP53
SCHEMBL25930932 0.78 MAPT (0.52) CTDSP1POLBKMT2AKDM4ETP53
SCHEMBL25933155 0.76 MEN1 (0.56) POLBKMT2AKDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 CTDSP1 2570/4885POLB 2630/4885KMT2A 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback